

# SYNTHESIS AND BIOLOGICAL ACTIVITY OF ALDIMINE DERIVATIVES BEARING 1,2,4-TRIAZOLE-3-THIOLYL MOIETY

Aida Šermukšnytė<sup>1\*</sup>, Ilona Jonuškienė<sup>1</sup>, Kristina Kantminienė<sup>2</sup>, Ingrida Tumosienė<sup>1</sup>


<sup>1</sup> Department of Organic Chemistry, Kaunas University of Technology, Kaunas

<sup>2</sup> Department of Physical and Inorganic Chemistry, Kaunas University of Technology, Kaunas

\* aida.sermuksnyte@ktu.edu

1,2,4-Triazole scaffold is a promising pharmacophore due to biological activity of its derivatives and extensive structural modification capability. 1,2,4-Triazole-3-thione derivatives as well as aldimine derivatives bearing various heterocyclic moieties possess antimicrobial, antioxidant, anticancer, anticonvulsant, anti-inflammatory, antiviral, antipyretic, etc. activity.

The target aldimine derivatives **4-13** were synthesized from 1,2,4-triazol-3-yl-thioacetohydrazide **3** and corresponding aldehydes in methanol (Scheme 1) [1,2].



**Scheme 1.** Synthesis of 1,2,4-triazol-3-yl-thioacetohydrazides **4-13**

Screening of the antioxidant activity of the synthesized compounds **4-13** has revealed that *N'*-(4-methylbenzylidene)-2-((4-phenyl-5-(2-(phenylamino)ethyl)-4*H*-1,2,4-triazol-3-yl)thio)acetohydrazide (**4**) possesses the highest DPPH radical scavenging activity as determined by DPPH radical scavenging assay and 2-((4-phenyl-5-(2-(phenylamino)ethyl)-4*H*-1,2,4-triazol-3-yl)thio)-*N'*-(pyridin-3-ylmethylene)acetohydrazide (**7**) exhibits the strongest reducing activity as identified by the reducing power assay. 2-((4-Phenyl-5-(2-(phenylamino)ethyl)-4*H*-1,2,4-triazol-3-yl)thio)-*N'*-(pyridin-4-ylmethylene)acetohydrazide (**6**) has shown the highest antibacterial activity against *Escherichia coli*, *Rhizobium radiobacter*, and *Xanthomonas campestris* bacteria among the tested compounds **4-13** by agar diffusion method.

**Acknowledgements.** The research leading to these results has received a funding from European Social Fund (project No 09.3.3-LMT-K-712-22-0083) under grant agreement with the Research Council of Lithuania (LMTLT).

## References

- I. Tumosienė, K. Kantminienė, I. Jonuškienė, A. Peleckis, S. Belyakov, V. Mickevičius. *Molecules*, 24 (2019) 971.
- I. Tumosienė, K. Kantminienė, A. Pavilonis, Ž. Maželienė, Z.J. Beresnevičius. *Heterocycles*, 78 (2009) 59.